Driving discovery of next-gen biomarkers with novel immunoproteomics technologies and services.
Transform your cancer research with i-Ome Cancer, the largest cancer-focused protein microarray on the market.
The perfect solution for biomarker discovery, i-Ome Discovery profiles autoantibodies against 1800+ human protein antigens, spanning numerous functions and disease areas, with two isotypes (IgG, IgA, or IgM).
Diversity. Precision. Specificity.
Sengenics has launched i-Ome® Cancer, an advanced protein microarray designed for rapid characterization of the immune system’s response to cancer.
Sengenics has entered into a sales distribution and services agreement with Chinese distributor Shanghai Universal Biotech Co., Ltd. This agreement marks a significant step in expanding the reach of Sengenics’ KREX® technology for immunoprofiling in Asia.
Alfatec Advanced Lab Solutions brings the Sengenics Microarray Technology to Italy
With over 30 years experience, Alfatech has been helping match Italian researchers with the tools they need to advance their aims and help the Italian community.
Visit Alfatec at:
Where: Aalborg University
When: January 17 13:00 – 16:00
Schedule: Meeting in Network on Proteins – Danish Life Science Cluster
Proteigene is an official distribution partner of Sengenics, the immunoproteomics company, for the French community. Proteigene has been working for more than 20 years in the proteomic research area and this partnership is an excellent opportunity to accelerate proteomics research and biomarker discovery.
Visit Proteigene’s website for more information about services in France:
SML Meditree is a leading MFDS-certified GCLP institution in Seoul, South Korea that provides a variety of clinical sample analyses services to pharmaceutical companies, bio-ventures, food industries, and researchers to help advance their clinical trials and research projects. They provide high-quality analyses and rapid services to accelerate new drug developments worldwide. With Sengenics new proteomics technology, they will be able to provide additional proteomics services to assist with biomarker discovery, patient stratification strategies for clinical research and therapeutics, and outcome predictions.
Learn more about SML Meditree
What makes an ideal biomarker and how do you measure? Professor Blackburn recently shared his insights with Drug Discovery World.
Have a listen:
Learn how to accelerate biomarker discovery with autoantibodies HERE
Our patented KREX® protein folding technology provides unique capabilities that accelerate the discovery of clinically relevant biomarkers.
Featured Service
Discover and validate new autoantibody biomarkers and biomarker signatures with unmatched specificity and reproducibility.
